Denali Therapeutics Inc (NASDAQ: DNLI) – Time For Strategy Change?

Denali Therapeutics Inc (NASDAQ:DNLI) currently has a daily average trading volume of 1.22M but it saw 2213281 shares traded in last market. With a market cap of 3.09B USD, the company’s current market price of $21.65 came rising about 3.29 while comparing to the previous closing price of $20.96. In past 52 weeks, the stock remained buoying in the range of price level as high as $30.79 and as low as $14.56.

Taking a look at 20-day trading activity of Denali Therapeutics Inc (DNLI) gives us an average price of $21.73, while its current price level is -29.68% below from 52-week high level whereas it is 48.70% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $20.10 while that of 200 days or SMA-200 reads an average of $19.41. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.63% during that period while stretching the period over a month that increases to 5.07%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.29 which implies that the stock is in neutral territory.

#####

#####

The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Citigroup which initiated the stock as “Buy” in its note to investors issued on December 13, 2023, recommending a price target of $32 for it. Cantor Fitzgerald issued its recommendations for the stock as it resumed the price target for the stock in the range of between $85 and $35.

Over the week, DNLI’s stock price is moving -0.41% down while it is 4.24% when we observe its performance for the past one month. Year-to-date it is 0.89% up and over the past year, the stock is showing a downside performance of -25.78%.

#####

Currently, Denali Therapeutics Inc’s total number of outstanding shares is 138.39M. Company’s return on investment (ROI) stands at -9.16% and return on equity (ROE) at -11.33%. Stock’s beta reads 1.38. Stock has a price to book (P/B) ratio of 2.12 while price to sale or P/S ratio amounts to 10.45. Its return on asset (ROA) is -9.18% on average.

#####